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Abstract
Objective—To identify plasma biomarkers that can be early predictors of mortality in critically 
ill patients with primary influenza A/H1N1.
Design—A prospective, multicenter, case-cohort pilot study.
Setting—Three academic ICUs.
Patients—Fifteen patients with primary influenza A/H1N1 that included 7 survivors and 8 non-
survivors. For comparison, age- and gender-matched healthy controls (n=27) were also studied.
Interventions—Plasma was prepared from whole blood drawn upon ICU admission in influenza 
patients (ICU day 1). Microvesicle tissue factor (MV-TF) activity, thrombin-antithrombin 
complexes (TATc), and D-dimers were measured as procoagulant markers and markers of 
activation of coagulation. Plasma cytokine levels were measured on the same blood samples in a 
subset of 12 influenza patients using the Luminex Multi-Analyte Profiling system. Patients were 
followed for the primary outcome of 28-day mortality.
Measurements and Main Results—The average admission APACHE II score of the patients 
was 25.5±9.3, 60% of patients had shock, and the 28-day mortality rate was 53.3% (n=8/15). 
Influenza patients had dysregulated indices of coagulation and inflammation compared to controls. 
Among the markers of activation of coagulation measured on ICU day 1, only increased MV-TF 
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activity was significantly associated with subsequent influenza-related mortality (5.6±1.2 pg/ml in 
non-survivors vs. 1.8±0.8 pg/mL in survivors, p < 0.05). IL-8 was significantly higher in non-
survivors compared with survivors (71.8±29.1 pg/ml, n=5 vs. 17.3±3.7 pg/mL, n=7, p < 0.05). In 
addition, MV-TF activity and IL-8 levels were significantly and positively correlated (r2 = 0.60, 
P=0.003). Other cytokines, TATc, and D-dimer were not different between non-survivors and 
survivors and did not correlate with illness severity or mortality.
Conclusions—This study identifies an association between plasma IL-8 and MV-TF activity 
measured upon admission in patients with severe, primary influenza A/H1N1 infection and 
subsequent mortality. Thus, these biomarkers may serve as very early prognostic markers for 
patients with influenza A/H1N1.
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Introduction
Influenza A/H1N1 is a single-stranded RNA virus that causes a high number of intensive 
care unit (ICU) admissions, as well as considerable morbidity and mortality. Although 
effective treatments for influenza exist, treatment and triage decisions are still difficult 
because of a lack of accurate, reliable severity of illness predictive scores to determine the 
need for ICU admission (1). Patients with influenza have alterations in hemostatic 
parameters, thrombocytopenia, disseminated intravascular coagulation (DIC), and 
thrombosis (2). We have shown that platelets are activated in critically ill patients with 
primary 2009 influenza A /H1N1 (3). In addition, influenza A/H1N1 infection causes a 
“cytokine storm”. Given these prominent alterations in hemostasis and inflammation during 
influenza and their contribution to adverse outcomes, we sought to determine whether early 
indices of dysregulated coagulation and inflammation would be associated with influenza-
related mortality.
Circulating microvesicles (MVs, also called microparticles or extracellular vesicles) are 
small membrane fragments that can transfer mRNA and proteins between cells (4). MVs are 
particularly prothrombotic when displaying tissue factor (TF) (4). Viruses, such as influenza, 
induce TF expression in monocytes and endothelial cells and activate the coagulation 
cascade, which can result in DIC (5). Influenza virus H1N1 also activates platelets and 
induces the release of MVs (6). However, there are no studies reporting levels of circulating 
TF-expressing MVs during the course of human influenza. In this study, we measured levels 
of circulating MV-TF (MV-TF) activity and plasma cytokines in critically ill patients 
admitted with primary influenza A/H1N1and tested their association with adverse clinical 
outcomes.
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This was a prospective study of patients (n=15) with primary influenza A/H1N1 aged ≥21 
years enrolled within 24 hours of ICU admission. For comparison, age- and gender-matched, 
healthy, medication free, non-hospitalized, consenting control subjects aged ≥21 were also 
studied (n=27). The Institutional Review Boards approved this study (protocols 28210 and 
1005443) and all subjects or a legally authorized representative provided written informed 
consent. Influenza was diagnosed by reverse transcription polymerase chain reaction on a 
respiratory sample (Roche Applied Science, Germany). Patients with concurrent, secondary 
bacterial infection upon admission were excluded. The development of bacterial infections 
during patients’ ICU course was evaluated by blood, sputum, and urine cultures and 
serologies. Demographics, laboratory data, and illness severity scores were captured on all 
patients. Overt DIC was calculated according to the ISTH criteria, which has a high 
sensitivity and specificity for DIC but has some limitations such as accounting for temporal 
changes. Patients were followed prospectively for the primary outcome of all-cause, 28-day 
mortality.
Measurement of MV-TF activity, Markers of Activation of Coagulation and Cytokines
Plasma was prepared from ACD-anticoagulated whole blood drawn at the time of study 
enrollment via centrifugation (1500rpm for 20 minutes). Plasma was immediately frozen at 
−80°C until MV-TF, coagulation, and cytokine measurements. The levels of MV-TF activity 
in plasma were measured by an in-house two-step FXa generation assay (7). Briefly, MVs 
are pelleted by centrifugation of 200 µL of plasma and washed twice to remove the plasma. 
MVs are re-suspended in buffer and incubated with FVIIa (2.5 nM), FX (300 nM) and 
CaCl2 (10 mM) for 2 hours at 37°C in the presence of either an inhibitory anti-TF antibody 
(HTF-1) or a control antibody. Finally, levels of FXa are determined by adding a 
chromogenic substrate for 15 minutes at 37°C and measuring the absorbance at 405 nM with 
a VERSAmax microplate reader. The level of MV-TF activity in healthy controls is <0.05 
pg/mL. Recombinant human TF (Innovin; Dade Berhing, Marburg, Germany) was used as a 
standard. Plasma levels of thrombin antithrombin complexes (TATc, normal <4.0 ng/mL) 
and D-dimer (normal <500 ng/mL) were quantified by ELISA using the TAT Enzygnost 
Micro Kit (Dade Behring/Siemens) and Asserachrom D-dimer kit (Diagnostica Stago), 
respectively. Plasma cytokine levels were measured using the Luminex Multi-Analyte 
Profiling system (LabMAP™) technology.
Statistical Analyses
Data were examined for normality using skewness and kurtosis tests. Summary statistics 
were determined using STATA (v11.0). Groups were compared using the Student’s t-test and 
the Chi-squared test, as appropriate (GraphPad Software, v5.0; STATA v11.0). Regression 
analyses were used to identify significant correlations between coagulation parameters and 
mortality. A two-tailed P value < 0.05 was considered significant.
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Upon ICU admission, all influenza A/H1N1 patients had acute respiratory distress requiring 
intubation and more than 50% of patients had shock requiring vasopressors (Table 1). 
Control subjects were well matched to influenza patient on the variables of age and gender, 
and as expected had very low levels of MV-TF activity (Table 1). Influenza patients had 
significantly higher plasma fibrinogen levels (571±67mg/dL vs. 308±18mg/dL, P < 0.001) 
and C-reactive protein (11.0±2 vs. 2.2±0.9, P < 0.001), consistent with a systemic 
inflammatory response and activation of the coagulation system during influenza.
However, while procoagulant markers and markers of activation of coagulation were all 
increased in patients with influenza compared to controls, only MV-TF activity was 
associated with influenza-related mortality, being significantly higher in non-survivors 
compared with survivors (Table 1, Figure 1A). Platelet counts and fibrinogen levels were 
slightly lower in non-survivors but did not reach significance (Table 1). MV-TF activity, 
TATc levels, and D-dimer did not correlate with APACHE II score, platelet count, fibrinogen 
levels, CRP, or age and did not significantly differ between male and female influenza 
patients or between patients with severe sepsis versus septic shock (not shown).
Next, we examined plasma cytokine levels in influenza patients and controls. IL-2R, IL-8 
and IL-10 were increased in patients with influenza A/H1N1 compared to control subjects 
whereas IL-1β, IL-2, IL-4, IL-5. IL-12, IL-13, IL-17, and CD40L were not changed (Table 
1). We previously reported that IL-6 is also increased in influenza A/H1N1 patients (3), 
consistent with the systemic inflammatory milieu during influenza. However, within the 
group of cytokines that increased in patients only IL-8 was significantly associated with 
influenza-related mortality, being higher in non-survivors compared with survivors (Figure 
1B). Interestingly, MV-TF activity significantly correlated with IL-8 levels (Figure 1C).
Discussion
In this study, we report that plasma MV-TF activity and IL-8 levels are increased in patients 
with primary influenza A/H1N1 and are significantly associated with influenza-related 
mortality. Our study is consistent with a previous paper that showed four chemokines (IL-8, 
IP-10, MCP-1 and MIG) were associated with fatal outcome in patients infected with 
influenza A (H5N1)(8). Other procoagulant markers and markers of inflammation or 
activation of coagulation were generally increased in patients with influenza but did not 
differ between survivors and non-survivors. Influenza virus can induce the expression of TF 
and the release of MVs, promoting a dysregulated pro-coagulant milieu (6). We posit that 
MV-TF activity in patients with influenza may not merely be a marker of severe infectious 
disease but may also contribute to adverse events such as vascular thrombosis, organ failure, 
and death. Further studies are needed to extend these studies and to examine the biological 
functions of MV-TF during influenza infection.
Our measurements of circulating MV-TF activity and IL-8 levels were made within 24 hours 
of ICU admission and robustly identified patients who did not survive their infectious 
course. As such, MV-TF activity and IL-8 may have utility as an early prognostic marker for 
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patients with influenza A/H1N1. These findings build on and extend observations made in 
bacterial sepsis and acute allograft rejection, where TF+ MVs correlate with adverse clinical 
outcomes (9–11). Moreover, since early plasma-based biomarkers for predicting influenza-
related mortality remain largely absent, these results may be utilized to improve 
prognostication and risk-stratification efforts in the early stages of treatment for patients 
with severe influenza. In addition, our findings may help identify patients where more 
intensive monitoring or treatment may be warranted, for example admission to an ICU 
setting.
The strengths of this study include its prospective multi-center design, robust determination 
of illness severity and complications, comprehensive characterization of markers of systemic 
activation of coagulation and inflammation, and inclusion of a matched healthy control 
cohort. The primary limitation of the study is the small sample size and therefore one must 
be cautious with interpretation of the data. Additional studies are needed to confirm our 
findings. However, critically ill patients with primary influenza A/H1N1 are challenging to 
prospectively identify and recruit. Thus, smaller studies of this nature are not uncommon 
within this field.
We also found that plasma IL-8 levels significantly correlated with MV-TF activity in 
influenza patients. Notably, there were no differences between influenza survivors and non-
survivors with regards to demographics, illness-severity, shock, DIC, or the need for and 
duration of mechanical ventilation. Thus, we do not believe that our findings that MV-TF 
activity and IL-8 were associated with mortality are due simply to confounding bias. 
Moreover, our findings highlight that traditional risk factors do not correlate with influenza-
related mortality, as also described by others (2).
While the precise mechanism underlying our findings that MV-TF activity and IL-8 were 
significantly correlated and predicted influenza mortality are unknown, we hypothesize that 
convergent signaling pathways through monocytes, macrophages, or other cells may 
contribute to the increased MV-TF activity and IL-8 levels seen in our patients. Taken 
together, the findings of our study demonstrate, for the first time to our knowledge, that MV-
TF activity and IL-8 levels may have clinical utility as early biomarkers to identify influenza 
patients at increased risk of mortality.
Conclusions
This study demonstrates that MV-TF activity and IL-8 levels in patients with severe, primary 
influenza A/H1N1 infection are early markers associated with subsequent influenza-related 
mortality.
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Figure 1. MV-TF activity and IL-8 as biomarkers are associated with mortality in patients with 
influenza A/H1N1 infection
(A) Plasma levels of microvesicle tissue factor (MV-TF) activity in survivors (white, n = 7) 
and non-survivors (black, n = 8). (B) Plasma levels of interleukin 8 (IL-8) in survivors 
(white, n = 7) and non-survivors (black, n = 5). (C) Correlation between MV-TF activity and 
IL-8 levels in H1N1 influenza-infected patients are shown (n = 12, each). Data (mean ± 
SEM) were analyzed by Student’s t-test (A and B) and linear regression analyses (C), and 
statistical significances are shown as *P<0.05.
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